Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
Insilico Medicine ·
In brief: Insilico Medicine reported on 25 Oct 2026: “Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026”. This page links to the original article and to related global AI stories tracked by Deekoya AI.
Read the full story on Insilico MedicineExplore more: Today in AI · Research papers · AI tools · Learn AI
Related stories
- YourStory.com · 2 Nov 2026Meta is building humanoid robots with Fourier: What we know
- Wired AI · 2 Nov 2026When You Should—and Shouldn’t—Use AI to Search the Web
Chatbots are often quite good at retrieving the information you want from the web. But sometimes you’ll get better results by typing your query into a good old search engine.
- Columbia Missourian · 2 Nov 2026Students for Human Intelligence platforms AI concerns for Mizzou
- HCI Innovation Group · 2 Nov 2026AI Innovations and Disruptors in Healthcare
- Dealroom · 2 Nov 2026CareLumi raises $2.5M to verify AI running inside healthcare
- The Decoder · 2 Nov 2026Saudi Aramco takes 49 percent stake in AI firm Humain with $2.6 billion deal
Saudi Aramco is buying into Humain, the company meant to turn Saudi Arabia into a global AI hub. The article Saudi Aramco takes 49 percent stake in AI firm Humain with $2.6 billion deal appeared first on The Decoder .
Who reported “Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331…”?
Insilico Medicine, on 25 Oct 2026. The full article is at the source link on this page.